Tiziana Life Sciences is trading 14.99% up at $0.77 in pre-market on November 3 after its November 2 announcement of positive topline Phase 2a INFORM-MS results. - The 50-microgram dose met the neuroinflammation endpoint versus placebo; both doses met the safety and tolerability endpoint. - The 100-microgram dose showed no significant difference on the imaging measure, and disability scores were unchanged. - The company plans further analysis and discussions with the FDA; available coverage did not provide pre-market volume.